Europe Advanced Therapy Medicinal Products CDMO Market Report 2023: Featuring Thermo Fisher, AGC Biologics, Minaris Regenerative Medicine, Lonza Group & More

Dublin, March 01, 2023 (GLOBE NEWSWIRE) -- The "Europe Advanced Therapy Medicinal Products CDMO Market Size, Share & Industry Trends Analysis Report By Indication, By Product, By Phase, By Country and Growth Forecast, 2022-2028" report has been added to's offering.

The Europe Advanced Therapy Medicinal Products CDMO Market would witness market growth of 16.5% CAGR during the forecast period (2022-2028).

The study of ATMPs is a field that is experiencing rapid expansion, though the majority of the developed products are still in the early stages of research. The ongoing combined trials and the possible development to treat severe chronic illnesses have led the probability of ATMPs being available on the market soon.

Targeted medicines have made it possible for there to be new trial techniques, and ATMPs could profit from these new trial methodologies to acquire early access. The majority of consumers also anticipate CDMOs to provide their knowledge in many processes even after manufacturing, such as during product launches.

This is primarily due to CDMO's growing customer base, which includes smaller biotech companies in addition to the major pharmaceutical corporations. In addition, many smaller biotech firms put a lot of effort into developing their drug pipelines without any manufacturing background. The early incorporation of smaller biotech enterprises' activities is thus made possible by using CDMOs' assistance in development and manufacturing operations.

The European Medicines Agency's Committee for Advanced Therapies (CAT) is tasked with evaluating marketing authorization (MA) requests for ATMPs and making scientific recommendations for the categorization of ATMPs, among other duties. The EMA and the European Commission released a joint action plan with the intention of streamlining procedures and better addressing the unique needs of ATMP developers. Such developments in the field of gene and cell therapy are propelling the growth of the advanced therapy medicinal products CDMO market in the coming years.

The Germany market dominated the Europe Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $749.2 million by 2028. The UK market is anticipated to grow at a CAGR of 15.5% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 17.3% during (2022 - 2028).

Scope of the Study
Market Segments Covered in the Report:
By Indication

  • Oncology
  • Cardiology
  • Central Nervous System & Musculoskeletal
  • Infectious Disease
  • Dermatology
  • Endocrine, Metabolic, Genetic
  • Immunology & Inflammation
  • Ophthalmology
  • Hematology
  • Gastroenterology
  • Others

By Product

  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered & Others

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

  • Thermo Fisher Scientific, Inc. (Patheon, Inc.)
  • AGC Biologics, Inc. (AGC, Inc.)
  • Catalent, Inc
  • Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
  • WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
  • Lonza Group AG
  • Celonic AG (JRS PHARMA GmbH & Co. KG)
  • Rentschler Biopharma SE
  • Bio Elpida (Polyplus-transfection SA.)

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2019, Jan - 2022, Aug) Leading Players

Chapter 4. Europe Advanced Therapy Medicinal Products CDMO Market by Indication
4.1 Europe Oncology Market by Country
4.2 Europe Cardiology Market by Country
4.3 Europe Central Nervous System & Musculoskeletal Market by Country
4.4 Europe Infectious Disease Market by Country
4.5 Europe Dermatology Market by Country
4.6 Europe Endocrine, Metabolic, Genetic Market by Country
4.7 Europe Immunology & Inflammation Market by Country
4.8 Europe Ophthalmology Market by Country
4.9 Europe Hematology Market by Country
4.1 Europe Gastroenterology Market by Country
4.11 Europe Others Market by Country

Chapter 5. Europe Advanced Therapy Medicinal Products CDMO Market by Product
5.1 Europe Gene Therapy Market by Country
5.2 Europe Cell Therapy Market by Country
5.3 Europe Tissue Engineered & Others Market by Country

Chapter 6. Europe Advanced Therapy Medicinal Products CDMO Market by Phase
6.1 Europe Phase I Market by Country
6.2 Europe Phase II Market by Country
6.3 Europe Phase III Market by Country
6.4 Europe Phase IV Market by Country

Chapter 7. Europe Advanced Therapy Medicinal Products CDMO Market by Country

Chapter 8. Company Profiles

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.